Proactiveinvestors Australia HemoGenyx Pharmaceuticals Proactiveinvestors Australia HemoGenyx Pharmaceuticals RSS feed en Fri, 19 Jul 2019 13:49:39 +1000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - CDX Patent Application ]]> Fri, 12 Jul 2019 16:00:04 +1000 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> Wed, 03 Jul 2019 16:00:10 +1000 <![CDATA[RNS press release - Result of AGM ]]> Fri, 28 Jun 2019 21:19:22 +1000 <![CDATA[RNS press release - Development of ApbHC ]]> Mon, 24 Jun 2019 16:00:09 +1000 <![CDATA[RNS press release - CDX Effective as Conditioning Therapeutic in vivo ]]> Wed, 12 Jun 2019 16:00:02 +1000 <![CDATA[RNS press release - CDX Antibody is Effective against AML in vivo ]]> Wed, 05 Jun 2019 17:15:05 +1000 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Fri, 31 May 2019 01:40:35 +1000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Fri, 31 May 2019 01:35:46 +1000 <![CDATA[RNS press release - CDX Antibody is Effective against ALL in vitro ]]> Thu, 30 May 2019 16:00:04 +1000 <![CDATA[RNS press release - Posting of Annual Report and Notice of AGM ]]> Tue, 28 May 2019 16:00:09 +1000 <![CDATA[RNS press release - Variation of Terms of Warrant Instrument ]]> Wed, 15 May 2019 16:00:03 +1000 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> Wed, 01 May 2019 16:00:14 +1000 <![CDATA[RNS press release - Final Results for the Year Ended 31 December 2018 ]]> Tue, 30 Apr 2019 00:10:17 +1000 <![CDATA[RNS press release - Presentation at Cancer Immunotherapy Conference ]]> Wed, 30 Jan 2019 18:00:02 +1100 <![CDATA[RNS press release - Operations Update ]]> Mon, 07 Jan 2019 18:00:04 +1100 <![CDATA[RNS press release - Directorate Change ]]> Thu, 20 Dec 2018 18:00:06 +1100 <![CDATA[RNS press release - Directorate Change & Appointment ]]> Mon, 05 Nov 2018 18:00:06 +1100 <![CDATA[RNS press release - Orgenesis collaboration for Hu-PHEC development ]]> Mon, 22 Oct 2018 17:00:06 +1100 <![CDATA[RNS press release - Collaboration, License and Investment by Orgenesis ]]> Fri, 19 Oct 2018 17:00:03 +1100 <![CDATA[RNS press release - Collaboration with Johnson & Johnson Innovation ]]> Mon, 15 Oct 2018 17:00:04 +1100 <![CDATA[RNS press release - Half-year Report ]]> Fri, 28 Sep 2018 18:30:03 +1000 <![CDATA[RNS press release - Change of Adviser ]]> Fri, 28 Sep 2018 16:00:12 +1000 <![CDATA[RNS press release - Hemogenyx to present at Oxford conference ]]> Mon, 03 Sep 2018 16:00:06 +1000 <![CDATA[RNS press release - Result of AGM ]]> Wed, 27 Jun 2018 20:39:56 +1000 <![CDATA[Media files - HemoGenyx CEO 'overwhelmed' by speed of progress at the company ]]> Tue, 26 Jun 2018 16:15:00 +1000 <![CDATA[RNS press release - Investor presentation ]]> Fri, 08 Jun 2018 16:00:06 +1000 <![CDATA[RNS press release - Posting of Annual Report & Notice of AGM ]]> Wed, 06 Jun 2018 03:05:43 +1000 <![CDATA[RNS press release - Development Agreement ]]> Mon, 14 May 2018 16:00:11 +1000 <![CDATA[News - Hemogenyx teams up with global pharma company to help further develop CDX antibodies ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) has signed a deal with an unnamed global pharma company to help develop its CDX antibodies – the company’s flagship treatment for blood cancer.

It is hoped these antibodies will eliminate the need for chemotherapy and radiotherapy by killing only “unwanted” cells and allowing more people who would otherwise be deemed unfit enough to receive a bone marrow transplant.

READ: Hemogenyx aims for blood cancer treatment revolution

The antibodies are currently in pre-clinical trials with a phase I study pencilled in for early next year.

Hemogenyx said Monday’s deal boosts its chances of getting the antibodies into clinical trials and beyond.

Under the agreement, the global pharma company will provide Hemogenyx with free technical support, access to advanced methods of engineering antibodies as well as other things that should aid development.

In return, the pharma company will receive a research licence for anything jointly-developed under the agreement, as well as an option for an exclusive worldwide license to commercially exploit CDX antibodies or any variants, which will be jointly developed under the agreement.

Should the partner not exercise that option, Hemogenyx can license the jointly developed CDX antibodies or any variants.

WATCH: HEMO bosssays progress 'surpassing expectations'

“This agreement provides additional support for our development plans for CDX antibodies, and complements the work that we are already undertaking with our own resources,” said chief executive Vladislav Sandler.

“This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major global pharmaceutical company with the benefit of their global reach and large-scale resources.”

Hemogenyx shares soared 24% to 4.72p.

Mon, 14 May 2018 08:08:00 +1000
<![CDATA[Media files - HemoGenyx CEO says progress 'definitely surpassing expectations' ]]> Fri, 11 May 2018 10:00:00 +1000 <![CDATA[RNS press release - Research Collaboration with Rockefeller University ]]> Tue, 08 May 2018 16:00:13 +1000 <![CDATA[News - HemoGenyx signs collaboration agreement with Rockefeller University to develop new Lupus treatments ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) has entered into a collaboration agreement with Rockefeller University to use its new type of humanised mice for autoimmune disease modelling in an effort to develop new treatment for autoimmune diseases, specifically Lupus.

Under the agreement, the collaborative work will be co-led by investigators at HemoGenyx and Rockefeller with professor Alexander Tarakhovsky acting as the principal investigator for Rockefeller and Dr Vladislav Sandler acting as the principal investigator for Hemogenyx.

WATCH: HemoGenyx CEO says progress 'definitely surpassing expectations'

The biotechnology company said its directors are confident that the collaboration does not require forms of funding that would be dilutive to HemoGenyx shareholders.

Vladislav Sandler, CEO and co-founder of HemoGenyx, said: “This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding.”

He added: ”Shareholders can now also see the potential for the use of our technology beyond our current bone marrow transplantation focus to treat debilitating and otherwise incurable autoimmune diseases such as Lupus.”

HemoGenyx said the first stage of development work will create mice that emulate the human symptoms of Lupus, while the second stage will then focus on the development of multi-specific antibodies and cell therapies to treat the disease in these mice.

Vladislav Sandler said: “The attractiveness of our new type of humanized mice to major biotechnology companies and leading research institutes will give us further opportunities to collaborate on other disease models and specific drug development.”

Tue, 08 May 2018 07:40:00 +1000
<![CDATA[RNS press release - Final Results ]]> Tue, 01 May 2018 01:23:15 +1000 <![CDATA[News - Hemogenyx Pharmaceuticals chief hails a year of significant progress ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) chief executive Dr Vladislav Sandler described 2017 as a “significant year” after the company listed on the market and inked a collaboration with Oxford University.

But perhaps the most exciting development occurred after the period-end as the company was able to show that its CDX antibodies can attack and eliminate acute myelogenous leukaemia.

While the data emanated from a pre-clinical study, it was nevertheless encouraging.

In Monday's full-year results statement, shareholders were told work is “progressing successfully” towards  the goal of submitting an investigational new drug application to the US Food and Drug Administration for its CDX antibodies product.

Lake Pharma deal

During the 12 months ended December 31, the company appointed Lake Pharma supplier of CDX antibodies, while the tie-up with Oxford University will help accelerate development of Hemogenyx's blood cancer treatments.

"2017 was a significant year for Hemogenyx as we successfully listed the business on the London Stock Exchange and raised the financing necessary to further develop novel therapies with the potential to transform the lives of bone marrow transplant patients,” said CEO Sandler.

“We remain on track in the development of both of our products according the timescale we outlined to investors in October. We continue to successfully develop our Hu-PHEC cell therapy product and we are on course to have our CDX antibodies product in readiness for the start of phase I trials as planned.”

In common with companies at this formative stage of development Hemogenyx was loss-making. The deficit was £2.32mln. The company was sitting on just under £1.9mln of cash at the period-end.

Mon, 30 Apr 2018 16:36:00 +1000
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> Thu, 12 Apr 2018 02:15:43 +1000 <![CDATA[RNS press release - Directorate Change ]]> Tue, 03 Apr 2018 16:00:10 +1000 <![CDATA[News - Hemogenyx appoints Marc Feldmann, pioneer of anti-TNF therapy for rheumatoid arthritis, as its new executive chairman ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) has announced the appointment of Sir Marc Feldmann as its new executive chairman with effect from 9 April 2018.

The biotechnology group noted that Feldmann has a “unique blend of scientific, medical and commercial experience and expertise”, pointing out that he shares the academic credit for inventing and developing an anti-TNF therapy for rheumatoid arthritis - the first use of monoclonal antibodies in a common disease.

READ: Hemogenyx shares leap as it signs collaboration deal with major US biotechnology company

HemoGenyx said Feldmann was previously chairman of the company’s scientific advisory board and has a “remarkably broad experience” of discovering new medicines, testing ideas and leading clinical trials.

Following the changes, Robin Campbell, currently Hemogenyx's chairman, will become a non-executive director and Adrian Beeston, its non-executive director, will step down from the board, both with the immediate effect.

Vladislav Sandler, HemoGenyx's CEO, said: “Since Sir Marc has been at the forefront of  promoting effective scientific-medical-pharmaceutical interactions, he has built up a huge network of friends and collaborators who meet regularly in Oxford and they will help Hemogenyx grow and go clinical.”   

In early morning trading, the company’s shares were up 6.4% at 2.90p.

Tue, 03 Apr 2018 08:15:00 +1000
<![CDATA[RNS press release - Second Price Monitoring Extn ]]> Wed, 14 Mar 2018 22:05:17 +1100 <![CDATA[RNS press release - Price Monitoring Extension ]]> Wed, 14 Mar 2018 22:00:13 +1100 <![CDATA[RNS press release - Collaboration with major US biotechnology company ]]> Tue, 13 Mar 2018 18:00:06 +1100 <![CDATA[News - Hemogenyx shares leap as it signs collaboration deal with major US biotechnology company ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares jumped by over a quarter in value on Tuesday boosted by news the firm has entered into a collaboration with a major US biotechnology company in a deal worth up to approximately US$250,000 for the UK firm.

The biotechnology group said the collaboration follows on from the announcement made by the company on 26 February 2018, which confirmed the filing of a provisional patent application relating to its development of a new type of humanised mice with a chimeric mouse-human blood system.

READ: Hemogenyx shares soar after news of first solid data on leukaemia treatment

The firm added that this application of Hemogenyx's humanized mice as a tool for drug development and testing forms the basis of its collaboration with the unnamed US biotech company.

It said the collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the company and has the potential to generate further income as the collaboration develops.

Dr Vladislav Sandler, Hemogenyx’s CEO & co-founder, commented:  The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate."

In early morning trading, Hemogenyx shares were up 25% at 3.88p.

 -- Adds share price --

Tue, 13 Mar 2018 07:36:00 +1100
<![CDATA[RNS press release - Advisory Board Appointment ]]> Tue, 06 Mar 2018 18:00:05 +1100 <![CDATA[RNS press release - Align Research Initiation of Coverage ]]> Thu, 01 Mar 2018 18:00:19 +1100 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Wed, 28 Feb 2018 03:40:57 +1100 <![CDATA[RNS press release - Price Monitoring Extension ]]> Wed, 28 Feb 2018 03:35:24 +1100 <![CDATA[RNS press release - Stmnt re Share Price Movement ]]> Tue, 27 Feb 2018 01:17:03 +1100 <![CDATA[News - HemoGenyx shares soar after news of first solid data on leukemia treatment ]]> HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares leapt 120% higher on Monday after it confirmed an earlier enigmatic tweet by saying it is "excited" by first data results from its lead product for the treatment of leukaemia.

All the tweet had said was “A serious breakthrough in the lab”, but it sent the AIM-listed firm's shares soaring first thing, prompting the group to release a regulatory news statement announcing that it has filed a provisional patent application relating to the development of a new type of humanised mice with a chimeric mouse-blood system that can be used to advance product development, as well as for other disease modelling and drug development.

READ: Hemogenyx happy with progress and recent collaborations

The company also noted that first data results have shown that its lead product, CDX bi-specific antibodies, are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro.

Using these new humanised mice, HemoGenyx said it is confident that it should be able to demonstrate that CDX bi-specific antibodies are effective in the treatment of AML.

Dr Vladislav Sandler, CEO and co-founder of the company, commented: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against Acute Myelogenous Leukemia.

"The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases."

He continued: “In addition, the new type of humanised mice opens the door to extending our work into other disease models and specific drug development which we expect to be of great interest to large biopharmaceutical companies and could form the basis of a number of significant future collaborations.”   

In late afternoon trading, HemoGenyx's shares were up 123% at 4.75p. The company added that it regrets the "premature disclosure" of the tweet which it said "is not in accordance with the Company's policies on the release of information".

Mon, 26 Feb 2018 15:03:00 +1100
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> Mon, 12 Feb 2018 18:00:05 +1100 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> Wed, 07 Feb 2018 18:00:03 +1100 <![CDATA[RNS press release - Hemogenyx Welcomes N.Y. Lt. Governor to its Labs ]]> Thu, 11 Jan 2018 18:00:04 +1100